CRPC w/ Bone Metastases

Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617. March 16, 2020

The Relationship Between Total Lesion Activity on 18F Choline Positron Emission Tomography-Computed Tomography and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer Bone Metastases Treated with 223Radium. March 11, 2020

Safety and activity of radium-223 in metastatic castration-resistant prostate cancer: the experience of Istituto Nazionale dei Tumori. March 9, 2020

Feasibility Study and Preliminary Results of Prognostic Value of Bone SPECT-CT Quantitative Indices for the Response Assessment of Bone Metastatic Prostate Carcinoma to Abiraterone. March 2, 2020

Overall survival and second primary malignancies in men with metastatic prostate cancer. February 25, 2020

Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421. July 23, 2019

Prognostic Value of 18F-Fluorocholine PET Parameters in Metastatic Castrate-Resistant Prostate Cancer Patients Treated with Docetaxel. May 9, 2019

Incidence of Second Primary Malignancies in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the United States. May 1, 2019

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program. January 11, 2019

Patient Selection for Radium-223 Therapy in Patients With Bone Metastatic Castration-Resistant Prostate Cancer: New Recommendations and Future Perspectives. January 4, 2019

Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223. January 3, 2019

Reversibility of castration resistance status after Radium-223 dichloride treatment: Clinical evidence and Review of the literature. December 20, 2018

Evaluating radium-223 response in metastatic castration-resistant prostate cancer with imaging. December 3, 2018

The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer November 23, 2018

Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects October 15, 2018

Targeted Alpha Therapy, an Emerging Class of Cancer Agents - A Review September 21, 2018

Microscopic Imaging Pierces the “Black Box” of Cancer Bone Metastasis August 1, 2018

Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial May 17, 2018

Radiation for Treatment of Painful Bone Metastases May 15, 2018

Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases March 20, 2018

Page 1 of 10